Skip to content

Author

Tomoko Kutomi

We have 1 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025.

In Japan, JN.1-adapted mRNA vaccination, including the sa-mRNA vaccine, was estimated to provide protection against symptomatic SARS-CoV-2 infection among older adults in Japan.

H. Maeda, Ataru Igarashi, Shinya Mitsui et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.